Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 June 2024 | Story Carmenita Redcliffe-Paul
Global Citizen Invitation Prof Thuli Madonsela 4 July 2024

The University of the Free State (UFS) and the South African Chamber of Commerce United Kingdom (SACC UK) are pleased to present a Global Citizen Series conversation, South Africa’s Future in Focus: the post-election impact on social justice, service delivery, higher education, and the economy, from the perspective of Prof Thuli Madonsela, Director of the Centre for Social Justice in the Faculty of Law at Stellenbosch University and Professor of Law in the Law Trust Research Chair in Social Justice Studies.

As part of the Global Citizen Webinar Series, Prof Madonsela – a member of the International Anticorruption Advisory Council and Global Justice Leaders – will join UFS Vice-Chancellor and Principal, Prof Francis Petersen, and SACC UK Chairperson, Sharon Constançon, for a conversation that explores what the future holds for social justice, service delivery, higher education, and the economy in South Africa.

After thirty years of democracy, South Africans once again made their mark on 29 May 2024 in one of the most pivotal elections since 1994. Join us in person during the Free State Arts Festival or online as we explore South Africa’s Future in Focus: The post-election impact on social justice, service delivery, higher education, and the economy.

Date: Thursday 4 July 2024
In-person event SA time: 18:00-20:00 SAST, Centenary Complex, UFS Bloemfontein Campus
Webinar SA time: 18:30-19:30 / UK time: 17:30-18:30

The livestream link will be shared with those who RSVP

Enquiries: Tebello Leputla - leputlatb@ufs.ac.za +27 51 401 3966

About Prof Thuli Madontsela

Prof Thuli (Thulisile) Madonsela is the Director of the Centre for Social Justice (CSJ) in the Faculty of Law at Stellenbosch University and Professor of Law in the Law Trust Research Chair in Social Justice Studies. She is the founder of the Thuma Foundation for Democracy Leadership and Literacy and a member of the African Academy of Sciences. She was recently appointed to the UN Scientific Advisory Board and as Chairperson of Cities Alliance. She is a member of the International Anticorruption Advisory Council and Global Justice Leaders.

The former Public Protector of South Africa and full-time Commissioner in the South African Law Reform Commission was one of the 11 technical experts who helped draft the South African Constitution, and is a co-architect of several constitutionally mandated laws, including the Equality Act, Employment Equity Act, and the Promotion of Administrative Justice Act. She has an extensive background in applied constitutional, social justice, and administrative law principles, mainly based on her years of public service and her investigation of improper conduct in state affairs as Public Protector. A regular sought-after keynote speaker, Prof Madonsela has written, taught, presented papers, and published on these matters and ethical leadership, good governance, and gender mainstreaming for decades.

Prof Madonsela helped draft several international human rights instruments at UN, AU, and SADC levels, as well as country reports on such matters. She currently teaches Constitutional Law, Social Justice Law, Administrative Law, and Constitutional Governance and Ethical Leadership. She holds eight honorary law doctorates, in addition to two law degrees, a Harvard Advanced Leadership Certificate, and other postgraduate qualifications.

Named one of Time’s 100 most influential people in the world in 2014, Prof Madonsela’s global recognition includes more than 70 awards, including Rotary’s Paul Harris award, the Commonwealth Lawyers Truth and Justice award, and the global ACFE’s Cressy award. Prof Madonsela is a mother of two, a philanthropist, and an avid mountaineer who has summited Mt Kilimanjaro twice under the #Trek4Mandela-#Caring4Girls anti-period poverty campaign and the Musa Plan for Social Justice, and regularly hikes for the #Action4Inclusion campaign, a quest to end student debt.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept